Murray Yule

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition

Loredana Santo, Sonia Vallet, Teru Hideshima et al. · Oncogene · 2010 · 141 citations · Full text

Hematological Malignancy, Gsk-3β Activation, Medicine +8

First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors

Geoffrey I. Shapiro, Eunice L. Kwak, Bruce J. Dezube et al. · Clinical Cancer Research · 2014 · 86 citations

A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck

Robert I. Haddad, Lisa J. Weinstein, Tad J. Wieczorek et al. · Clinical Cancer Research · 2004 · 66 citations · Full text

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies

Hendrik‐Tobias Arkenau, Ruth Plummer, L. Rhoda Molife et al. · Annals of Oncology · 2011 · 65 citations · Full text

Medicine, Receptor Tyrosine Kinase, Small Molecule Inhibitor +6

A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study

Lucas Moreno, Lynley V. Marshall, Andrew D.J. Pearson et al. · Clinical Cancer Research · 2014 · 55 citations